Snapshot Of The Opioid Crisis, An Infographic
The opioid market is expected to total $18.4bn by 2020 – but the growing crisis of opioid abuse plagues manufacturers, policy makers and public health. Scrip takes a look at the pipeline of abuse-deterrent formulations and physician opinions about what impact those will have.
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
Final data comparing cabotegravir to Truvada for HIV prophylaxis confirms superiority. ViiV says treatment data in women may enable an all-gender approval that eluded Gilead with Descovy.